Table 2. Intent-To-Treat (n=59) Analysis Results.

	Riluzole				Placebo				Treatment effect		Cohen's d, 95% CI
	Baseline		Week 12		Baseline		Week 12
	EMM	SD	EMM	SD	EMM	SD	EMM	SD	Fa	P
Primary outcomes (LMM)
CY-BOCS total	27.24	3.78	21.76	6.28	29.13	3.59	22.46	5.68	0.04	0.84	(−0.44, 0.58)
CY-BOCS obsessions	13.52	2.20	10.73	3.60	14.57	1.98	11.02	3.27	0.00	1.00	(−0.36, 0.66)
CY-BOCS compulsions	13.72	2.05	11.01	3.63	14.57	1.87	11.46	3.25	0.21	0.65	(−0.53, 0.49)
CGAS	41.59	7.57	46.91	9.29	40.17	7.68	47.72	8.60	0.77	0.38	(−0.66, 0.36)
CGI-S	5.59	0.63	5.04	0.92	5.63	0.67	5.03	0.84	0.001	0.98	(−0.49, 0.53)
Secondary outcomes (RM-ANOVA)b
RBS-R total score	22.14	15.13	18.24	15.51	28.03	15.13	22.93	15.29	0.35	0.55	(−0.68, 0.36)
MASC total score	57.31	11.41	54.20	11.8	59.93	12.10	57.10	12.37	0.00	0.98	(−0.47, 0.57)
CDI total score	50.78	8.86	49.38	9.03	51.70	9.17	49.04	9.26	0.43	0.52	(−0.74, 0.34)

Abbreviations: CGAS, Children's Global Assessment Scale; CGI-S, Clinical Global Impressions-Severity; CY-BOCS, Children's Yale-Brown Obsessive–Compulsive Scale; EMM, estimated marginal mean.

Full linear mixed model included fixed effects for time, treatment group (RIL vs PLA), and the time by treatment group interaction, as well as the baseline value of the respective outcome variable as a covariate for the primary measures. Estimated marginal means reflect group means adjusted for any covariate (baseline level of the outcome). Cohen's d reflects group differences in change scores (week 12−baseline) calculated using last observation carried forward.

^adf for primary outcome measures (1, 58). df for secondary outcome measures: RBS-R (1, 56); MASC (1,55); CDI (1, 52).

^bRM-ANOVA uses last observation carried forward.